poisar

Stock

Roivant Sciences Ltd. ROIV

$37.40+1.74%

Overview

ROIV market data

Price History

ROIV price chart · 1M
O
36.85
H
37.79
L
36.54
C
37.40
Vol
237,509.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$36.85
Previous Close
$36.76
Day High
$37.79
Day Low
$36.54
52 Week High
$37.92
52 Week Low
$27.48
7 Day Return
+1.56%
30 Day Return
+10.59%
90 Day Return
+24.65%
1 Year Return
+35.95%
Daily Notional Volume
$8.9M
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.43
Diluted earnings per share over the trailing twelve months.
Beta
1.11
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-3,535.0%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$11.60 – $37.97
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $26.2B · P/B 4.38 · P/S 3,479.27.

Company News

9 captured
Roivant's Priovant Says FDA Approved LISRAYA For Dermatomyositis In Adults, First Targeted Therapy For The Disease; Available In U.S. ImmediatelyBenzinga · Aug 27, 2026, 7:29 PM
Why Is Arbutus Biopharma Stock Gaining Friday?Benzinga · Aug 21, 2026, 4:36 PM
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $46Benzinga · Aug 10, 2026, 3:07 PM
Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $42Benzinga · Aug 7, 2026, 4:57 PM
HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $41Benzinga · Aug 7, 2026, 1:12 PM
Roivant's Priovant Announces First Patients Enrolled In Global Phase 3 BEACON+ Study Of Brepocitinib In Cutaneous Sarcoidosis; Topline Data Expected In 2028Benzinga · Aug 6, 2026, 11:21 AM
8-K filing — Roivant Sciences Ltd. (ROIV)SEC EDGAR · Aug 6, 2026, 11:13 AM
Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M EstimateBenzinga · Aug 6, 2026, 11:12 AM
Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis StudyBenzinga · Jun 25, 2026, 6:00 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock